| Dr Bradley Mark King, MD, MPH | |
|
1016 Kirkpatrick Rd, Burlington, NC 27215-9714 | |
| (336) 228-0254 | |
| (336) 584-0101 |
| Full Name | Dr Bradley Mark King |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 13 Years |
| Location | 1016 Kirkpatrick Rd, Burlington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043504152 | NPI | - | NPPES |
| 1043504152 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 201500553 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alamance Regional Medical Center | Burlington, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alamance Eye Care Pa | 6103722699 | 10 |
News Archive
The president has been using the refrain "Change is . . . " to catalogue a list of actions -; including rescuing the auto industry, enacting health care reform and ending the war in Iraq -; he hopes will increase his reelection chances.
When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.
AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.
› Verified 7 days ago
| Entity Name | Alamance Eye Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184641524 PECOS PAC ID: 6103722699 Enrollment ID: O20031208000222 |
News Archive
The president has been using the refrain "Change is . . . " to catalogue a list of actions -; including rescuing the auto industry, enacting health care reform and ending the war in Iraq -; he hopes will increase his reelection chances.
When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.
AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradley Mark King, MD, MPH 1016 Kirkpatrick Rd, Burlington, NC 27215-9714 Ph: (336) 228-0254 | Dr Bradley Mark King, MD, MPH 1016 Kirkpatrick Rd, Burlington, NC 27215-9714 Ph: (336) 228-0254 |
News Archive
The president has been using the refrain "Change is . . . " to catalogue a list of actions -; including rescuing the auto industry, enacting health care reform and ending the war in Iraq -; he hopes will increase his reelection chances.
When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.
AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States. In a study published this month in Blood, the Penn team describes the strategy, based on the oldest part of the human immune system - called "complement" - that could turn out to be less costly and more effective for the majority of patients with a rare blood disorder.
Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.
› Verified 7 days ago
Chadwick R Brasington, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1016 Kirkpatrick Road, Burlington, NC 27215 Phone: 336-228-0254 Fax: 336-584-0101 | |
William Louis Porfilio, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1016 Kirkpatrick Road, Burlington, NC 27215 Phone: 336-228-0254 Fax: 336-584-0101 | |
Steven Andrew Dingeldein, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1016 Kirkpatrick Road, Burlington, NC 27215 Phone: 336-228-0254 Fax: 336-584-0101 | |
Dr. Nisha Mukherjee, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 1016 Kirkpatrick Rd, Alamance Eye Center, Burlington, NC 27215 Phone: 336-228-0254 | |
Charles Ford Sydnor, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1016 Kirkpatrick Road, Burlington, NC 27215 Phone: 336-228-0254 Fax: 336-584-0101 | |
Blake Maxwell Hampton, MD Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 1016 Kirkpatrick Rd, Burlington, NC 27215 Phone: 336-228-0254 Fax: 336-584-0101 |